A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

Researchers at the University of North Carolina found that a once-weekly injection of Ozempic could cut cravings at its lowest dose level.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

SZA Last week Weeks at no. 1 Weeks on chart Top Dawg/RCA/Sony Music Week of February 1, 2025 click to see more Top Dawg/RCA/Sony Music Rimas/Sony Music ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide. Topline results from the Phase 2b ...